Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of "Buy" from Analysts

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has earned an average recommendation of "Buy" from the eleven ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $12.50.

A number of brokerages recently issued reports on CATX. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. Royal Bank of Canada dropped their target price on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating on the stock in a research report on Thursday, March 27th. Truist Financial dropped their target price on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Brookline Capital Management upgraded Perspective Therapeutics to a "strong-buy" rating in a report on Monday, March 10th. Finally, Wedbush restated an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, May 13th.

Perspective Therapeutics Stock Up 4.7%

Perspective Therapeutics stock traded up $0.12 during mid-day trading on Friday, reaching $2.70. 602,672 shares of the company were exchanged, compared to its average volume of 1,032,825. Perspective Therapeutics has a 12-month low of $1.60 and a 12-month high of $16.55. The business has a fifty day moving average of $2.25 and a 200 day moving average of $3.13.

Insider Transactions at Perspective Therapeutics

In related news, CEO Johan M. Spoor bought 22,026 shares of the company's stock in a transaction on Friday, March 28th. The stock was bought at an average cost of $2.24 per share, with a total value of $49,338.24. Following the completion of the acquisition, the chief executive officer now owns 59,383 shares in the company, valued at approximately $133,017.92. This represents a 58.96% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert F. Williamson III acquired 22,192 shares of the company's stock in a transaction dated Friday, March 28th. The shares were acquired at an average cost of $2.27 per share, with a total value of $50,375.84. Following the completion of the purchase, the director now owns 70,837 shares in the company, valued at approximately $160,799.99. This represents a 45.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 115,696 shares of company stock worth $256,344. Company insiders own 3.52% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CATX. JPMorgan Chase & Co. increased its stake in Perspective Therapeutics by 24.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company's stock valued at $333,000 after buying an additional 4,844 shares during the period. SG Americas Securities LLC raised its stake in shares of Perspective Therapeutics by 41.3% in the 4th quarter. SG Americas Securities LLC now owns 26,088 shares of the company's stock valued at $83,000 after buying an additional 7,627 shares in the last quarter. Wealth Effects LLC raised its stake in shares of Perspective Therapeutics by 186.8% in the 4th quarter. Wealth Effects LLC now owns 38,000 shares of the company's stock valued at $121,000 after buying an additional 24,750 shares in the last quarter. Koa Wealth Management LLC acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $83,000. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $51,000. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.